Newsroom | 71273 results
Sorted by: Latest
-
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial...
-
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026
CHICAGO--(BUSINESS WIRE)--Massive Bio today announced the next-generation product suite within Reticulum Nexus™, introducing a coordinated set of AI agents, intelligent calculators, signal engines, patient navigation tools, and physician referral workflows designed to move oncology access from fragmented trial matching to closed-loop orchestration. The new suite brings together Patient Connect™, TrialRelay™, NexusPulse™, Sentinel Agents™, DrArturo AI™, and Phoebe AI™ into a real-time multi-agen...
-
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr...
-
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek t...
-
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026
DURHAM, N.C. & SEATTLE--(BUSINESS WIRE)--Tune Therapeutics, a leading epigenome editing company, presented new data today at the European Association for the Study of Liver (EASL) Congress in Barcelona, Spain, demonstrating the first clinical evidence of epigenetic silencing in hepatitis B virus (HBV). The oral presentation was delivered by Dr. Ed Gane, Professor of Medicine at the University of Auckland and world-renowned authority on HBV. The phase 1b/2a clinical trial evaluated the safety an...
-
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO...
-
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer...
-
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo...
-
Samenvatting: BeOne Medicines stelt norm voor langdurige ziektecontrole bij CLL met BRUKINSA-gegevens van 78 maanden op ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, vernieuwt het behandelingsparadigma voor chronische lymfatische leukemie (CLL) tijdens de jaarlijkse bijeenkomst van de American Society of Clinical Oncology (ASCO) in 2026. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldi...
-
Riassunto: BeOne Medicines definisce uno standard per il controllo della malattia a lungo termine nella LLC con i dati a 78 mesi di BRUKINSA all'ASCO 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), un'azienda oncologica a livello globale, sta portando avanti il paradigma terapeutico nella leucemia linfatica cronica (LLC) al Meeting annuale 2026 dell'American Society of Clinical Oncology (ASCO). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al tes...
